News

Novartis23h
Teresa Jose
As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...
Novartis6d
Novartis completes acquisition of Regulus Therapeutics
We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...
Novartis1mon
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...
Novartis2mon
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease Lead asset for ADPKD ...
Novartis3mon
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1; Phase III data showed ...
Novartis3mon
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR. New indication approximately triples eligible patient population, allowing Pluvicto ® to be used after one androgen receptor pathway inhibitor (ARPI) and ...
Novartis4mon
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in ...
Novartis5mon
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 | Novartis
Ad hoc announcement pursuant to Art. 53 LR. Full year. Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) . Sales growth driven by continued strong performance ...
Novartis7mon
Addressing unmet needs for inherited neuromuscular diseases
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation; Transaction includes enabling technology platforms and therapeutic ...
Novartis10mon
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR. Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a ...
Novartis10mon
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs.
Novartis11mon
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Priority Review based on ASC4FIRST Phase III study with Scemblix ® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of ...